REGENXBIO to Participate in Upcoming Investor Conferences

11/4/24 7:05:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RGNX alert in real time by email

ROCKVILLE, Md., Nov. 4, 2024 /PRNewswire/ -- REGENXBIO Inc. (NASDAQ:RGNX) today announced it will participate in the following investor conferences:

UBS Global Healthcare Conference

Fireside Chat: Wednesday, November 13 at 12:30 p.m. PT

Location: Rancho Palos Verdes, CA

Stifel 2024 Healthcare Conference

Fireside Chat: Tuesday, November 19 at 11:30 a.m. ET

Location: New York, NY

Piper Sandler 36th Annual Healthcare Conference

Fireside Chat: Thursday, December 5 at 9:30 a.m. ET

Location: New York, NY

Live webcasts of the fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma^® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack

Corporate Communications

[email protected]

Investors:

George E. MacDougall

Investor Relations

IR@regenxbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302294648.html

SOURCE REGENXBIO Inc.

Get the next $RGNX alert in real time by email

Recent Analyst Ratings for

$RGNX

Date	Price Target	Rating	Analyst
11/15/2024	$22.00	Overweight	Morgan Stanley
10/10/2024	$18.00	Outperform	Raymond James
6/7/2024	$38.00	Buy	Goldman
3/11/2024	$36.00	Buy	H.C. Wainwright
3/8/2024	$20.00 → $35.00	Sector Perform → Outperform	RBC Capital Mkts
3/6/2024	$37.00	Market Perform → Outperform	Leerink Partners
2/21/2024	$45.00	Outperform	Raymond James
11/1/2023	$35.00	Buy	Stifel

More analyst ratings

REGENXBIO to Participate in Upcoming Investor Conferences

Chat with this insight

Recent Analyst Ratings for $RGNX

$RGNX SEC Filings

SEC Form 10-Q filed by REGENXBIO Inc.

REGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

REGENXBIO Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

$RGNX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

Amendment: SEC Form SC 13G/A filed by REGENXBIO Inc.

$RGNX Financials

Live finance-specific insights

$RGNX Press Releases

Fastest customizable press release news feed in the world

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

$RGNX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Karabelas Argeris N exercised 10,000 shares at a strike of $3.76 and sold $101,052 worth of shares (10,000 units at $10.11) (SEC Form 4)

Chief Financial Officer Chan Mitchell was granted 58,869 shares (SEC Form 4)

SEC Form 3 filed by new insider Chan Mitchell

$RGNX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Morgan Stanley resumed coverage on REGENXBIO with a new price target

Raymond James resumed coverage on REGENXBIO with a new price target

Goldman initiated coverage on REGENXBIO with a new price target

$RGNX Leadership Updates

Live Leadership Updates

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

REGENXBIO Announces Leadership Transition

Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors

$RGNX Market Insights

Live Market Insights

Why Is Clearside Biomedical Stock Gaining Today?

REGENXBIO Expands Its AFFINITY DUCHENNE Trial To Include A New Cohort Of Younger Patients

FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy

Recent Analyst Ratings for
$RGNX

$RGNX
SEC Filings

$RGNX
Large Ownership Changes

$RGNX
Financials

$RGNX
Press Releases

$RGNX
Insider Trading

$RGNX
Analyst Ratings

$RGNX
Leadership Updates

$RGNX
Market Insights